Look and feel younger... today!

Millions of women already know BOTOX® Cosmetic— a nonsurgical treatment that helps temporarily improve moderate to severe frown lines between the brows.

Those moderate to severe vertical lines between the brows are sometimes referred to as 1’s, 11’s, or 111’s.

Years of squinting, concentrating, or frowning can cause your skin to furrow and crease. As time passes, your skin becomes less elastic and those moderate to severe frown lines remain—even when your muscles aren’t contracting.

With BOTOX® Cosmetic, you can get real, noticeable results and still look like yourself. So, you can still frown or look surprised, but without the wrinkles and creases between your brows.

Why consider BOTOX® Cosmetic? Botulinum toxins are biologics, a type of purified protein. Since biologics are made from living things, they are unique. So, even if a botulinum toxin product has the same ingredients as another, they may not have the same effect.1-3

Because biologics have a complex structure, it is difficult to recreate a product without knowing exactly how it’s made (which is specific to each manufacturer).8 That’s why the amount of the dose (Unit dosing) and formulations are different between products. Be sure to ask your healthcare professional if BOTOX® Cosmetic is right for you.

No surgery. No recovery time.

BOTOX® Cosmetic treatment is a quick, 10-minute procedure that requires no downtime or recovery—-it’s often called a lunchtime procedure.

With a few tiny injections, BOTOX® Cosmetic blocks nerve impulses to the muscles in your forehead—called the “corrugator” and “procerus” muscles— reducing their movement. This decreased muscle activity helps lessen the appearance of moderate to severe frown lines between the brows for real, noticeable results.


1. US Food and Drug Administration. Frequently asked questions about therapeutic biological products. US Food and Drug Administration website. /TherapeuticBiologicApplications/ucm113522.htm. Updated December 24, 2009. Accessed September 8, 2011. 2. Goldsmith D, Kuhlmann M, Covic A. Through the looking glass: the protein science of biosimilars. Clin Exp Nephrol. 2007;11(3):191-195. 3. Roger SD, Mikhail A. Biosimilars: opportunity or cause for concern? J Pharm Pharm Sci. 2007;10(3):405-410.